Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.69 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Codeinone SCHEMBL13952981 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL13633530 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL13154678 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL12137788 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL100655 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL14192923 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL3107493 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL29375985 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL7707098 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1OPRD1MRGPRX2PDE4D | |
| Codeinone SCHEMBL11533410 | 0.95 | OPRM1 (0.91) | OPRM1OPRK1OPRD1MRGPRX2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200338068-A1 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF a,ß-UNSATURATED KETONE COMPOUNDS | SpecGx LLC (US) | 2020-10-29 | — | — | US | disclosed |
| US-20180008596-A1 | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds | MALLINCKRODT LLC (US) | 2018-01-11 | — | — | US | disclosed |
| US-20160243113-A1 | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds | MALLINCKRODT LLC (US) | 2016-08-25 | — | — | US | disclosed |
| US-20150148365-A1 | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds | LIEBEL-FLARSHEIM COMPANY LLC | 2015-05-28 | — | — | US | disclosed |
| US-20150148365-A1 | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds | LIEBEL-FLARSHEIM COMPANY LLC | 2015-05-28 | — | — | US | disclosed |
| US-8871779-B2 | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds | MALLINCKRODT LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871779-B2 | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds | MALLINCKRODT LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8748611-B2 | Processes for preparing morphinan-6-one products with low levels of alpha beta-unsaturated compounds | MALLINCKRODT LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748611-B2 | Processes for preparing morphinan-6-one products with low levels of alpha beta-unsaturated compounds | MALLINCKRODT LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120059167-A1 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA BETA-UNSATURATED COMPOUNDS | MALLINCKRODT INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059167-A1 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA BETA-UNSATURATED COMPOUNDS | MALLINCKRODT INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20080312442-A1 | Process for Preparing Morphinan-6-One Products with Low Levels of Alpha, Beta-Unsaturated Ketone Compounds | SpecGx LLC | 2008-12-18 | — | — | US | disclosed |
| US-20080312442-A1 | Process for Preparing Morphinan-6-One Products with Low Levels of Alpha, Beta-Unsaturated Ketone Compounds | SpecGx LLC | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312442-A1 | Process for Preparing Morphinan-6-One Products with Low Levels of Alpha, Beta-Unsaturated Ketone Compounds | FASN, CYP1B1, SULT1A1 | OPRM1 73/4885OPRK1 105/4885OPRD1 46/4885 |
| US-20160243113-A1 | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds | FASN, CYP1B1, CLN6 | OPRM1 69/4885OPRK1 98/4885OPRD1 50/4885 |
| US-20200338068-A1 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF a,ß-UNSATURATED KETONE COMPOUNDS | FASN, CYP1B1, CLN6 | OPRM1 76/4885OPRK1 123/4885OPRD1 62/4885 |
| US-20150148365-A1 | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds | FASN, CYP1B1, CLN6 | OPRM1 69/4885OPRK1 98/4885OPRD1 50/4885 |
| US-20120059167-A1 | PROCESSES FOR PREPARING MORPHINAN-6-ONE PRODUCTS WITH LOW LEVELS OF ALPHA BETA-UNSATURATED COMPOUNDS | FASN, DEGS1, CYP1B1 | OPRM1 87/4885OPRK1 163/4885OPRD1 61/4885 |
| US-20180008596-A1 | Processes For Preparing Morphinan-6-One Products With Low Levels Of Alpha, Beta-Unsaturated Ketone Compounds | FASN, CYP1B1, CLN6 | OPRM1 69/4885OPRK1 98/4885OPRD1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.